Kornimate/medical-research-clean huggingface dataset:
early results of empyema thoracis treatment in children by video-assisted thoracoscopic surgery

Conditions: Empyema Thoracis in Children

Summary: the aim of study is to assess early results of empyema thoracis treatment in children by video-assisted thoracoscopic surgery


Eligibility criteria:
inclusion criteria: * all patients had empyema. * all patients had been treated by video-assisted thoracoscopic surgery in children hospital 1 from 01/01/2015 to 30/04/2019. exclusion criteria: * the patient had empyema caused by tuberculosis.

Keywords: empyema thoracis thoracoscopic vats video-assisted thoracoscopic surgery pediatric empyema thoracis
electrocardiographic modifications and spontaneous hypoglycemic episodes in type 1 diabetes

Conditions: Type 1 Diabetes Mellitus

Summary: the population of type 1 diabetes patients with cardiovascular disease is increasing and this study aims to explore the electrocardiographic changes that are associated with spontaneous hypoglycemia in this type of population. more precisely, this study will investigate if these modifications are of the same nature as those already observed in different populations (patients with type 2 diabetes) to see the pro-arrhythmogenic impact of hypoglycemia in patients with type 1 diabetes.


Eligibility criteria:
inclusion criteria: * men and women ≥ 18 years old; * be able to give informed consent; * diagnosis of type 1 diabetes for ≥ 6 months; * treated with intensive insulin therapy (multiple injections of insulin or insulin pump) and either * a history of cv disease defined as: 1) established diagnosis of atherosclerotic coronary artery disease (example: previous history of infarction); 2) previous cerebral vascular stroke or transient ischemic accident; 3) anterior revascularization of the coronary arteries, carotid artery or peripheral arteries; 4) at least one coronary stenosis, carotid artery or lower extremity arteries \> 50%; 5) history of symptomatic coronary heart disease confirmed with hospitalization or a positive stress test result or by any cardiac imaging result, or unstable angina with changes observed at the ecg; 6) asymptomatic cardiac ischemia confirmed by a nuclear imaging test, an exercise test, a dobutamine stress echo; 7) nyha ii-iii class chronic heart failure; 8) amputation of limb or foot due to circulatory insufficiency. * or more than 20 years duration of t1d and at least 2 of the following risk factors or associated condition: 1) chronic renal failure egfr \ 2); 3) hypertension or treatment for hypertension; 4) hyperlipidemia or treatment for hypolipemia; 5) abdominal obesity (waist circumference\> 94 cm for men and \> 80 cm for women); 6) smoking ; 7) significant retinopathy (pre-proliferative, proliferating, laser or intravitreous injection); 8) body mass index \> 30 kg /m2; 9) erectile dysfunction; 10) left ventricular hypertrophy; 11) positive family history of early mcas (h \< 55 years old and f \< 65 years old) exclusion criteria: * definitive criteria: 1) qrs \> 120 ms on the baseline ecg; 2) presence of atrial fibrillation at inclusion; 3) current intake of any drug that may prolong qt according to the judgment of the investigator and the update of the list available on www.professionsante.com. * transient criteria (the patient can be included once the anomaly is corrected): 1) hypokalemia (\< 3.5 mmol/l); 2) hypocalcemia (ionized calcium \< 1.10 mmol/l); 3) hypomagnesemia (\< 0.7 mmol/l)
prevalence and risk factors of erectile dysfunction in type 2 diabetic patients

Conditions: Type 2 Diabetic Patients; Erectile Dysfunction

Summary: the investigators evaluated 250 male, type 2 diabetic patients, aged 18-80 years. they will undergo iief (international index of erectile function), sas of zung (self-rating anxiety state)and sds of zung (self-rating depression scale)questionnaires. the investigators will evaluate anthropometric and biochemical parameters, dysautonomic function index, imt (intima media thickness) index, and fundus oculi examen. furthermore, the investigators will perform mnsi (michigan neuropathy screening instrument) and nds (neuropathy disability score)questionnaires.


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus exclusion criteria: * type 1 diabetes mellitus * \< 18 years old * anatomic abnormalities of the penis * patients taking erectile dysfunction therapy at the moment of the enrollment

Keywords: type 2 diabetes mellitus male erectile dysfunction
pharmacokinetics and safety of moxifloxacin

Conditions: Tuberculosis

Summary: the main objective of this prospective clinical trial is to compare pharmacokinetics and safety and tolerability of a standard dose (400 mg) with an escalated dose (600 mg; 800 mg) of moxifloxacin (mfx). this clinical trial will provide important safety information on mfx in a higher dosage in tb patients.

moxifloxacin (mfx) is a fluoroquinolone with a high in vitro and in vivo bactericidal activity against mycobacterium tuberculosis. a daily dose of 600-800 mg mfx should be considered for optimal killing of the involved mycobacteria and suppression of drug resistance, which is higher than the currently used dose of 400 mg once daily. in general, safety data to support switching to the suggested higher dose are limited. for this purpose, twenty tuberculosis patients will start on a standard dose of mfx 400 mg once daily. after 8 days the dose will be increased to 600 mg once daily and on the 15th day of treatment, the dose of mfx will be escalated to 800 mg. in patients who have been treated with rifampicin (rif) in the past three weeks prior to start of mfx treatment an additional washout period of 3 weeks to reduce the rifampicin induced enzymatic activity will precede the dose escalation.

Eligibility criteria:
inclusion criteria: * patients with tb, with mycobacterium tuberculosis (or m. africanum) by culture * starting treatment with mfx in a dose of 400 mg as part of their tb treatment exclusion criteria: * contra-indication for mfx * baseline qtc-interval \> 450 msec * history of resuscitation * history of ventricular tachycardia (including torsades de pointes) * family history of sudden cardiac death or torsades de pointes * additional risk factors for torsades de pointes (including known heart failure, left ventricular hypertrophy) * use of concomitant treatment with qt/qtc prolonging drugs (including anti-dysrhythmics class ia and iii, antipsychotics, tricyclic antidepressants or the antihistaminic drug terfenadine) * abnormal electrolytes (k, mg, na, ca) * abnormal cardiac repolarisation on screening/baseline ecg * history of adverse events to fluoroquinolones * hiv co-infection * rif treatment during last 3 weeks before start of the study. after a washout period of 3 weeks the patient can be included.

Keywords: tuberculosis moxifloxacin pharmacokinetics safety
avoiding diabetes after pregnancy trial

Conditions: Weight Reduction

Summary: the avoiding diabetes after pregnancy trial (adapt) study was designed to test the effectiveness of interventions that potentially increase the adoption of diabetes prevention program (dpp) elements by women who had a pregnancy with gestational diabetes mellitus (gdm). the study was conducted as an integrated trial with two separate arms: one to facilitate weight reduction and the other to increase diabetes testing. there were two hypotheses: 1. women in the testing intervention will be more likely to have received a diabetes test within the 6 months post-intervention than women in the control group. 2. women in the weight reduction intervention will have lost more weight at the 6-month and 9-month follow-up than women in the control group. the primary study aim was to determine the efficacy of a system of interactive technology-based supports to prompt women with a history of gestational diabetes to take steps to prevent diabetes. the secondary aims were focused on women's engagement: * to evaluate the impact of the weight reduction intervention in terms of participant engagement with the interactive technology-based supports. * to evaluate changes in the women's perception of their personal diabetes risk following after exposure to information about diabetes risk following a pregnancy with gdm. * to identify the determinants and motivators of and barriers to diabetes testing in the 6- to 12-week postpartum period and thereafter, using the health belief model to guide the study. there was an additional secondary aim involving metformin: * to evaluate the impact of the diabetes risk reduction intervention in terms of women seeking out their physician's advice on metformin treatment and receiving a metformin prescription, if appropriate.


Eligibility criteria:
inclusion criteria: general * history of gdm in the previous 6 months to 4.5 years * access to the internet and text messages or phone messages * current patient of harvard vanguard medical associates * 18 years of age or older * able to read in english weight reduction group * overweight or obese * capable of performing moderate physical activity diabetes testing group * had not competed a diabetes test (ogtt or fasting blood sugar at 6-12 weeks postpartum or ogtt, fasting blood sugar or hemoglobin a1c after 12 weeks postpartum) exclusion criteria: general: * diabetes diagnosis * psychotic disorder diagnosis * enrolled in a research study weight reduction group * taking prescription medications for weight loss * engaged in a formal weight reduction program diabetes testing group * history of postpartum ogtt, fasting plasma glucose or hemoglobin a1c (after 6 weeks postpartum)

Keywords: weight reduction behavioral intervention gestational diabetes mellitus type 2 diabetes diabetes testing
postoperative pain management in cerebral palsy - comparative observational study"

Conditions: Pain, Postoperative

Summary: in this study, our aim is to examine orthopedic interventions, anesthesia method, postoperative pain level and management applied to patients with cp in biruni university hospital.


Eligibility criteria:
inclusion criteria: * diagnosed with cerebral palsy between the ages of 3-15, * category 2 according to the classification of the american society of anesthesiology (asa 2), * patients undergoing soft tissue release for knee or ankle flexion contracture of the lower extremity with palliative or reconstructive hip interventions exclusion criteria: * any child with cp younger than 3 years old and older than 15 years has undergone * procedures without a specific diagnosis of cp, * the need for bone surgery, * requiring both hip, knee and ankle surgery in the same session, * with autonomic neuropathy, * patients with a history of anticholinergic and vasoactive drug use or allergy to amide type local anesthetics
retrospective study of trabectedin in soft tissue sarcomas

Conditions: Sarcoma, Soft Tissue

Summary: this is an independent, observational, retrospective post marketing study on the use of trabectedin in a clinical setting. a data collection on the clinical use of the drug will help to improve knowledge and might contribute to optimize the clinical use of the drug.

this is a national, multi-centre observational retrospective and prospective chart review study of treatment patterns and clinical outcomes in a subset of patients with soft tissue sarcoma who received trabectedin as per licensed indication. in the absence of availability of existing databases, a retrospective chart review design was selected. it is anticipated that the medical charts will contain the information required to answer study objectives. this chart review study will be conducted in 25 sites in italy an estimated total of 900 charts will be abstracted. this study requires no intervention or interference with standard medical care, and thus it will not affect patient treatment. the study is sponsored by italian sarcoma group charts of patients who initiated trabectedin as part of the approved treatment for a soft tissue sarcoma , will be identified by site staff. each identified chart will be assigned a unique study identification number. site staff will review the medical charts for all identified patients to determine patient eligibility. those patients who meet eligibility criteria will be enrolled into the final study cohort as subject. data from subject medical charts will be abstracted by local site study staff and entered at the site into an electronic data capture (edc) system. the system will also facilitate the monitoring of the completeness and quality of study data as the study data accrue.

Eligibility criteria:
inclusion criteria: * patients who received trabectedin according to the approved indication in the period january 2010 december 2015 exclusion criteria: * trabectedin started before january 2010 and after december 2015 * participation into clinical trials with trabectedin * clinical chart missing, empty, or not retrievable.

Keywords: trabectedin soft tissue sarcoma observational
maternal serum pentraxin 3 in early pregnancy to predict gestational diabetes mellitus

Conditions: Pregnancy Complications Affecting Fetus (Diagnosis)

Summary: to investigate the association of maternal serum concentrations of pentraxin 3 in early pregnancy with gestational diabetes mellitus and to explore its potential value in the prediction of gdm.

we recruited all pregnant women for the first checkup in our hospital . maternal fasting serum ptx3 levels, fasting plasma glucose and fasting insulin and other factors were measured. oral glucose tolerance test (ogtt) was performed at 24-28 weeks in all participants. according to the occurrence of gdm, subjects were divided into two groups: gdm group and normal glucose tolerance (ngt) group.

Eligibility criteria:
inclusion criteria: * women with maternal age ≥ 18 years, singleton pregnancy, primipara, no smoking, confirmed gestation≤20 weeks and spontaneous conception were invited to participate in the study. exclusion criteria: * women were excluded if they had multiple pregnancy, pre-gestational diabetes mellitus (pgdm), hypertensive disorders, preterm delivery, cardiovascular disease, immunological disease, glucocorticoid therapy, or other severe illness. in addition, women who were suffering from fetal abnormalities including chromosomally abnormal fetuses and/or structural defects and fetal growth restriction occurred during pregnancy were also excluded from the study.
link between eosinopenia and bacterial infections in the elderly subject hospitalized in geriatrics

Conditions: Fever; Leukocytes; C Reactive Protein (CRP) is Less Than 20 mg/ l

Summary: the main purpose of this monocentric, non-interventional, prospective study carried out in acute geriatrics (uga) and post-rehabilitation care, is to determine if eosinopenia is associated with bacterial infections.

it's a monocentric, non-interventional, prospective study carried. at inclusion: non-opposition will be collected by the investigator upon entering the geriatric unit. the investigators will have all the biological and radiological results and will decide whether or not to start antibiotic treatment. patients will be divided into 2 groups: group with bacterial infections and the other with non-bacterial diseases. the patient's socio-demographic data, reason for hospitalization, history, bmi, state of dependence (adl-iadl), mmse, treatments will be collected. biological examinations in the phase where an infection is not suspected will also be collected (nfs, ionogram, urea, creatinemia, albumin, pre albumin, crp, hepatocellular workup. clinical examination during the episode may be infectious as well that biological and radiological data will be collected as well as the diagnosis made. antibiotic treatment is prescribed will be listed. the blood levels of eosinophils between the two groups will be compared. follow-up at 1 month: the effectiveness of antibiotics will be evaluated on the absence of inflammatory syndrome and fever after the recommended antibiotic treatment and the duration of the recommended treatment. vital status will be collected.

Eligibility criteria:
inclusion criteria: * hospitalized in geriatrics. * first episode of: * fever\> 38 ° motivating the realization of a biological assessment. * or leukocytes\> 10 g / l and c reactive protein (crp) \> 20 mg / l. * be affiliated to a social security scheme. * no oral opposition to participation in the study and use of the data. exclusion criteria: * immunosuppression (hiv with cd4 \<200 / mm3) * active corticosteroid therapy * asthma * chemotherapy, immunosuppressive treatment * malignant hematological disease, lympho or myeloproliferative syndrome * antibiotic therapy initiated before entering the geriatric ward * documented parasitosis * eosinophilic vasculitis * stroke \<30 days * patient already included in another study * patient under guardianship or curatorship * not affiliated with a social security scheme * oral opposition to participation in the study

Keywords: eosinopenia bacterial infections
multisite pacing with a quadripolar lead

Conditions: Heart Failure

Summary: the purpose of this study is to evaluate the effects of multisite left ventricular (lv) biventricular (biv) pacing on lv hemodynamics in crt patients. it is hypothesized that the effect of simultaneous biv pacing utilizing multisite lv pacing on lv hemodynamics will be superior to conventional biv pacing.


Eligibility criteria:
inclusion criteria: * have a scheduled crt implantation at the participating clinical study site * have nyha functional class iii or iv, ejection fraction less than or equal to 35%, and qrs duration greater than 120ms * be undergoing a new st. jude medical crt-d device system (including lv lead) implantation * have the ability to provide informed consent for study participation and be willing and able to comply with the prescribed perioperative evaluations exclusion criteria: * have persistent or permanent atrial fibrillation * have an intrinsic heart rate of \<50 beats per minute * have a recent myocardial infarction within 40 days prior to enrollment * have undergone cardiac surgery or coronary revascularization procedure within 3 months prior to enrollment or be scheduled for such procedures * have had a recent cva or tia within 3 months prior to enrollment * have had intravenous inotropic support in the last 30 days * have ischemic etiology and are unable to tolerate stress echocardiography

Keywords: hemodynamic response cardiac resynchronization therapy
coconut oil in treatment of periodontitis

Conditions: Periodontal Diseases

Summary: virgin coconut oil (vco) is a vegetable oil extracted from coconut fleshcontains unsaturated fatty acids in the form of oleic acid and linoleic acid and flavonoids which function as anti-inflammatory. periodontitis is an inflammatory disease of the periodontal tissues with a high prevalence worldwide. the main etiology of plaque periodontitis is biofilm containing colonies of pathogenic microorganisms. the aim of the study is to evaluate and compare the effect of scaling and root debridement alone versus the use of topically applied coconut oil as adjunctive to scaling and root debridement in treatment of stage ii and iii grade b periodontitis.


Eligibility criteria:
inclusion criteria: * patients age group \>35 years without ant systemic disease * willing to take part in the study. patients with more than 16 natural teeth and have test teeth with both mesial and distal neighboring teeth with periodontitis with clinical attachment loss \>3 mm and radiographic percentage of bone loss/age ranged between 0.25 to 1. * patients with no history of allergies to coconut exclusion criteria: * smokers * pregnant * lactating women * teeth with both endodontic-periodontal lesion.

Keywords: periodontitis coconut oil scaling and debridement
the possible association between pseudoexfoliation syndrome and corneal endothelial cell changes

Conditions: Pseudoexfoliation Syndrome

Summary: the study aims to compare the endothelial cell count in patients with pseudoexfoliation syndrome to the the endothelial cell count in normal patients above the age of 50.

pseudoexfoliation syndrome is a systemic, age related condition, characterized by the deposition of a basement membrane like material within the anterior segment of the eye, most notably on the anterior lens capsule, the iris, the anterior chamber angle, and the anterior vitreous. both genetic and environmental factors may play a role in its pathogenesis . this condition may present unilaterally or bilaterally and is known to be a major risk factor for secondary open angle glaucoma. pseudoexfoliation glaucoma is seen in up to 50% of eyes with pseudoexfoliation. in contrast to primary open angel glaucoma, this disease runs a more aggressive clinical course with high intraocular pressure at onset, fast rate of progression, poor the response to medical therapy is, as well as increased need for surgical intervention. the prevalence of pseudoexfoliation syndrome demonstrates considerable geographic, ethnic and racial variation, ranging from low rates (\< 6% in patients older than 70 years) to higher rates (more than 15%) in other regions. in egypt, the reported incidence of pseudo-exfoliation syndrome in the population older than 40 years of age is 4.14%. several studies have shown the influence of pseudoexfoliation syndrome on the corneal endothelium cell density (ecd). multiple studies showed decreased ecds of patients with pseudoexfoliation syndrome compared to control patients. however, since the pseudoexfoliation syndrome varies greatly between different populations, in terms of prevalence and progression, it is valuable to study the potential corneal endothelial cell changes in an egyptian population. factors that can change corneal density include age, race, history of intraocular surgery, use of contact lenses and endothelial dystrophies. that's why in this study, history of intraocular surgery, corneal endothelial dystrophies and contact lens use are among exclusion criteria and includes patients 50 years in age or older.a low endothelial cell count may be a risk in cataract surgery if needed.

Eligibility criteria:
inclusion criteria: - pesudoexfoliation egyptian patients and controls groups must be at least 50 years old and matched from age. controls will be selected from the same outpatient clinic. exclusion criteria: * patients with history of previous intraocular surgeries, wearing contact lens and endothelial dystrophies.

Keywords: pseudoexfoliation syndrome corneal endothelial count
inosine energy expenditure study

Conditions: Healthy Volunteers

Summary: investigators want to test whether the intake of the nucleoside inosine increases the human energy expenditure. inosine occurs as a metabolic intermediate in the human body and is sometimes taken as a dietary supplement by athletes. for this purpose, investigators will measure the basal metabolic rate by indirect calorimetry. study participants will then take inosine dissolved in water or placebo and energy expenditure will be assessed again.


Eligibility criteria:
inclusion criteria: * healthy male volunteers * bmi between 18-27 kg/m2 * age between 18 and 40 years exclusion criteria: * chronic concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, diabetes mellitus), * known or suspected non-compliance, drug or alcohol abuse, * inability to follow the procedures of the study * participation in another study with investigational drug within the 30 days preceding and during the present study, * previous enrolment into the current study, * enrolment of the investigator, his/her family members, employees and other dependent persons, * thyroid disorders

Keywords: energy expenditure metabolism inosine